2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Melanoma
28
Carcinoma, Non-Small-Cell Lung
28
Neoplasm Metastasis
23
Carcinoma, Hepatocellular
22
Colorectal Neoplasms
19
Triple Negative Breast Neoplasms
16
Pancreatic Neoplasms
15
Neoplasms
15
Stomach Neoplasms
14
Squamous Cell Carcinoma of Head and Neck
13
Nasopharyngeal Carcinoma
13
Carcinoma, Renal Cell
13
Uterine Cervical Neoplasms
10
Rectal Neoplasms
10
Lymphoma
8
Sarcoma
7
Esophageal Squamous Cell Carcinoma
7
Esophageal Neoplasms
7
Recurrence
6
Lymphoma, Extranodal NK-T-Cell
6
Lung Neoplasms
6
Locally Advanced Rectal Cancer
6
Breast Neoplasms
6
Advanced Solid Tumor
6
Ovarian Neoplasms
5
Liver Neoplasms
5
Glioblastoma
5
Endometrial Neoplasms
5
Cholangiocarcinoma
5
Small Cell Lung Carcinoma
4
Interventions
spartalizumab
1
sintilimab
1
pyrotinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Digestive System Tumor
×
spartalizumab
×
Clear all
NCT07053150
2025-07-08
CCGLC-018
Tongji Hospital
Phase 2
Not yet recruiting
80 enrolled